These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30615933)

  • 1. Down syndrome: Neurobiological alterations and therapeutic targets.
    Vacca RA; Bawari S; Valenti D; Tewari D; Nabavi SF; Shirooie S; Sah AN; Volpicella M; Braidy N; Nabavi SM
    Neurosci Biobehav Rev; 2019 Mar; 98():234-255. PubMed ID: 30615933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Communication breaks-Down: from neurodevelopment defects to cognitive disabilities in Down syndrome.
    Contestabile A; Benfenati F; Gasparini L
    Prog Neurobiol; 2010 May; 91(1):1-22. PubMed ID: 20097253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down syndrome: from understanding the neurobiology to therapy.
    Gardiner K; Herault Y; Lott IT; Antonarakis SE; Reeves RH; Dierssen M
    J Neurosci; 2010 Nov; 30(45):14943-5. PubMed ID: 21068296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial dysfunction as a central actor in intellectual disability-related diseases: an overview of Down syndrome, autism, Fragile X and Rett syndrome.
    Valenti D; de Bari L; De Filippis B; Henrion-Caude A; Vacca RA
    Neurosci Biobehav Rev; 2014 Oct; 46 Pt 2():202-17. PubMed ID: 24548784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondria as pharmacological targets in Down syndrome.
    Valenti D; Braidy N; De Rasmo D; Signorile A; Rossi L; Atanasov AG; Volpicella M; Henrion-Caude A; Nabavi SM; Vacca RA
    Free Radic Biol Med; 2018 Jan; 114():69-83. PubMed ID: 28838841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synaptic pathology of Down syndrome.
    Garner CC; Wetmore DZ
    Adv Exp Med Biol; 2012; 970():451-68. PubMed ID: 22351068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The GABA
    Block A; Ahmed MM; Rueda N; Hernandez MC; Martinez-Cué C; Gardiner KJ
    Neuroscience; 2018 Feb; 372():192-212. PubMed ID: 29292072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The glutamatergic hypothesis for Down syndrome: the potential use of N-methyl-D-aspartate receptor antagonists to enhance cognition and decelerate neurodegeneration.
    Costa AC
    CNS Neurol Disord Drug Targets; 2014 Feb; 13(1):16-25. PubMed ID: 24152324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome.
    Altafaj X; Dierssen M; Baamonde C; Martí E; Visa J; Guimerà J; Oset M; González JR; Flórez J; Fillat C; Estivill X
    Hum Mol Genet; 2001 Sep; 10(18):1915-23. PubMed ID: 11555628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatty Acids: A Safe Tool for Improving Neurodevelopmental Alterations in Down Syndrome?
    Martínez-Cué C; Bartesaghi R
    Nutrients; 2022 Jul; 14(14):. PubMed ID: 35889838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GABAergic over-inhibition, a promising hypothesis for cognitive deficits in Down syndrome.
    Zorrilla de San Martin J; Delabar JM; Bacci A; Potier MC
    Free Radic Biol Med; 2018 Jan; 114():33-39. PubMed ID: 28993272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case report of the neurocognitive and behavioral phenotype of mosaic trisomy 14.
    Godfrey M; Udhnani M; Lee NR
    Neurocase; 2018; 24(5-6):250-254. PubMed ID: 30714851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lifespan analysis of brain development, gene expression and behavioral phenotypes in the Ts1Cje, Ts65Dn and Dp(16)1/Yey mouse models of Down syndrome.
    Aziz NM; Guedj F; Pennings JLA; Olmos-Serrano JL; Siegel A; Haydar TF; Bianchi DW
    Dis Model Mech; 2018 Jun; 11(6):. PubMed ID: 29716957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with corn oil improves neurogenesis and cognitive performance in the Ts65Dn mouse model of Down syndrome.
    Giacomini A; Stagni F; Emili M; Guidi S; Salvalai ME; Grilli M; Vidal-Sanchez V; Martinez-Cué C; Bartesaghi R
    Brain Res Bull; 2018 Jun; 140():378-391. PubMed ID: 29935232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular basis of pharmacotherapies for cognition in Down syndrome.
    Gardiner KJ
    Trends Pharmacol Sci; 2010 Feb; 31(2):66-73. PubMed ID: 19963286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prenatal treatment of Down syndrome: a reality?
    Guedj F; Bianchi DW; Delabar JM
    Curr Opin Obstet Gynecol; 2014 Apr; 26(2):92-103. PubMed ID: 24573065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translational validity and implications of pharmacotherapies in preclinical models of Down syndrome.
    Rueda N; Flórez J; Dierssen M; Martínez-Cué C
    Prog Brain Res; 2020; 251():245-268. PubMed ID: 32057309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurotransmitter-based strategies for the treatment of cognitive dysfunction in Down syndrome.
    Das D; Phillips C; Hsieh W; Sumanth K; Dang V; Salehi A
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Oct; 54():140-8. PubMed ID: 24842803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trans-acting epigenetic effects of chromosomal aneuploidies: lessons from Down syndrome and mouse models.
    Do C; Xing Z; Yu YE; Tycko B
    Epigenomics; 2017 Feb; 9(2):189-207. PubMed ID: 27911079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial dysfunction in down syndrome: molecular mechanisms and therapeutic targets.
    Izzo A; Mollo N; Nitti M; Paladino S; Calì G; Genesio R; Bonfiglio F; Cicatiello R; Barbato M; Sarnataro V; Conti A; Nitsch L
    Mol Med; 2018 Mar; 24(1):2. PubMed ID: 30134785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.